Zobrazeno 1 - 7
of 7
pro vyhledávání: '"David Chun Cheong Tsui"'
Autor:
David Chun Cheong Tsui, MD, PhD, Douglas E. Holt, MD, Tejas Patil, MD, Alyse Staley, MS, Dexiang Gao, PhD, Brian D. Kavanagh, MD, MPH, Erin L. Schenk, MD, PhD, Chad G. Rusthoven, MD, D. Ross Camidge, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 7, Pp 101516- (2024)
Purpose: We first described the role of local radiation therapy (LT) for oligoprogressive disease (OPD) on targeted therapy in 2012. Here, we present an updated and larger data set and extend the analysis beyond EGFR and ALK. Methods: A retrospective
Externí odkaz:
https://doaj.org/article/6457bcd9878a476a8dbc0f1b7dd0c6f7
Autor:
Brian D. Kavanagh, Candice Rossi, D. Ross Camidge, Tejas Patil, David Chun Cheong Tsui, Justin M. Honce
Publikováno v:
Clinical Lung Cancer. 23:e5-e8
Clinical Practice Points • Selpercatinib and pralsetinib both have high extracranial efficacy in RET fusion-positive non-small cell lung cancer (NSCLC). • We present a case of a patient with RET fusion-positive NSCLC who had a durable extracrania
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bcf5b417b6e2e2f093da78963d4f2a
https://doi.org/10.1016/j.cllc.2021.06.005
https://doi.org/10.1016/j.cllc.2021.06.005
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(6)
Brain metastases (BrM) are common in both non–small-cell lung cancer and small-cell lung cancer. Substantial progress in BrM management has occurred in the past decade related to advances in both radiation and medical oncology. Recent and ongoing r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97c3720ab40ed09fe4c8c36fff4733d
https://pubmed.ncbi.nlm.nih.gov/34985937
https://pubmed.ncbi.nlm.nih.gov/34985937
Autor:
David Chun Cheong Tsui, Jessica Kim Lee, Garrett M. Frampton, Khaled Tolba, Geoffrey R. Oxnard, D. Ross Camidge, Alexa Betzig Schrock
Publikováno v:
Journal of Clinical Oncology. 40:9123-9123
9123 Background: MET amplification (amp) can be a de novo driver or mechanism of resistance to targeted therapy. We explored the genomic landscape of MET amp NSCLC, including co-driver alterations and amplicon size, and its association with outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20f7164de2828103c6618bd18028181d
https://doi.org/10.1200/jco.2022.40.16_suppl.9123
https://doi.org/10.1200/jco.2022.40.16_suppl.9123
Autor:
Alexander R. Menter, Liming Bao, Dara L. Aisner, Hala Nijmeh, David Chun Cheong Tsui, D. Ross Camidge
Publikováno v:
Clinical lung cancer. 23(2)
Clinical Practice Points • HER2 amplification is an acquired resistance mechanism in ALK-rearranged non–small cell lung cancer. • FISH analysis revealed a minor subclone of HER2-amplified cells before becoming the dominant resistance mechanism.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea62b60892d5cf22e780cf7805e09077
https://pubmed.ncbi.nlm.nih.gov/34330640
https://pubmed.ncbi.nlm.nih.gov/34330640
Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6cb46935423e754611aa77a4fcddc7
https://pubmed.ncbi.nlm.nih.gov/33122107
https://pubmed.ncbi.nlm.nih.gov/33122107
Autor:
Tejas Patil, William T. Purcell, D. Ross Camidge, Paul A. Bunn, Jose Maria Pacheco, Andrew Nicklawsky, David Chun Cheong Tsui, Erin L. Schenk
Publikováno v:
Journal of Clinical Oncology. 39:9124-9124
9124 Background: Continuing a 1st generation EGFR TKI with chemotherapy upon TKI progression was not shown to be beneficial in the IMPRESS trial. However, the validity of this approach with osimertinib remains under explored. We attempted to characte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4f2e4144f83a92eb285b1ef5684ac53
https://doi.org/10.1200/jco.2021.39.15_suppl.9124
https://doi.org/10.1200/jco.2021.39.15_suppl.9124